Articles related to PROSTATE CANCER

A community oncologist previewed four ASCO 2026 late-breaking abstracts spanning pancreatic, prostate, lung, and sarcoma, flagging molecular testing infrastructure and toxicity coordination as key implementation questions ahead of the data readout.

Adding niraparib to abiraterone prolonged radiographic progression-free survival in BRCA-mutant metastatic hormone-sensitive prostate cancer, with overall survival data still maturing.

“At 10 years, BCF was 38.0% for HDR compared with 10.4% for SBRT.” — Udovicich et al., JAMA Network Open, February 2026

“The WOLVERINE meta-analysis provides the strongest evidence to date that MDT improves progression-free survival, radiographic progression-free survival, and castration resistance-free survival.” — Tang et al., The Lancet Oncology

Despite the scale of prostate-specific antigen (PSA) testing for prostate cancer screening, prediction models do not predict time-to-event end points or adjust for patient life expectancy.

Although men in this cohort have a good prognosis, this finding is clinically relevant, as change in PSA is a factor in determining whether men opt to remain on [active surveillance].